Key regions: Australia, Germany, United Kingdom, United States, France
Sierra Leone, a country in West Africa, has seen a gradual increase in the demand for immunosuppressants in recent years.
Customer preferences: Sierra Leone has a high prevalence of infectious diseases, including HIV/AIDS, malaria, and tuberculosis. As a result, there is a high demand for immunosuppressants in the country to manage these diseases. Additionally, there is a growing awareness among the population about the benefits of immunosuppressants in treating autoimmune diseases such as rheumatoid arthritis and lupus.
Trends in the market: The immunosuppressants market in Sierra Leone has been growing steadily due to the increasing prevalence of infectious diseases and autoimmune diseases. The market is dominated by generic drugs, which are more affordable for the majority of the population. There is also a trend towards the use of biologic drugs, which are more effective but also more expensive than generic drugs.
Local special circumstances: One of the challenges in the immunosuppressants market in Sierra Leone is the lack of access to healthcare services in rural areas. This makes it difficult for patients in these areas to access immunosuppressants and other essential medicines. Additionally, there is a lack of awareness among healthcare providers about the proper use of immunosuppressants, which can lead to misuse and adverse effects.
Underlying macroeconomic factors: Sierra Leone is one of the poorest countries in the world, with a GDP per capita of less than $600. This means that the majority of the population cannot afford expensive immunosuppressants, which limits the growth of the market. Additionally, the country has a weak healthcare system, which makes it difficult to distribute and administer immunosuppressants effectively. The government has been implementing reforms to improve the healthcare system, but progress has been slow due to limited resources.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
